CD30/TNFRSF8 Protein, Human, Recombinant (hFc & Avi), Biotinylated

Catalog No. TMPY-06282 Copy Product Info

CD30/TNFRSF8 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 67.02 kDa and the accession number is P28908-1.

CD30/TNFRSF8 Protein, Human, Recombinant (hFc & Avi), Biotinylated

Catalog No. TMPY-06282

Copy Product Info

CD30/TNFRSF8 Protein, Human, Recombinant (hFc & Avi), Biotinylated

Pack Size	Price	USA Stock	Global Stock
5 μg	$167	7-10 days	7-10 days
10 μg	$277	7-10 days	7-10 days
20 μg	$462	7-10 days	7-10 days
50 μg	$746	7-10 days	7-10 days
100 μg	$1,230	7-10 days	7-10 days

Add to Cart

Add to Quotation

For In stock only · Estimated delivery:USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	Immobilized Human CD30L hFc at 2 μg/mL (100 μL/well) can bind Human CD30/TNFRSF8 hFc & AVI, Biotinylated, the EC50 of Human CD30/TNFRSF8 hFc & AVI, Biotinylated is 30-130 ng/mL.
Description	CD30/TNFRSF8 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 67.02 kDa and the accession number is P28908-1.
Species	Human
Expression System	HEK293 Cells
Tag	C-hFc-Avi
Accession Number	P28908-1
Synonyms	tumor necrosis factor receptor superfamily, member 8,Ki-1,D1S166E,CD30
Construction	A DNA sequence encoding the human TNFRSF8 (NP_001234.2) (Met1-Lys379) was expressed with a c-terminal AVI tagged Fc region of human IgG1 at the C-terminus (Fc-AVI). The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. Predicted N terminal: Phe19
Protein Purity	> 90 % as determined by SDS-PAGE.
Molecular Weight	67.02 kDa (predicted); 110.33 kDa (reducing conditions)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor (TNFR) superfamily. CD30 protein is expressed by activated, but not resting, T and B cells. CD30 can regulate proliferation of lymphocytes and may also play an important role in human immunodeficiency virus replication. As a regulator of apoptosis, CD30 protein induces cell death or proliferation, depending on the cell type, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. CD30 protein expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs), and CD30 is also linked to leukocytes in patients with chronic inflammatory diseases, including lupus erythematosus, asthma, rheumatoid arthritis and atopic dermatitis (AD).Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy